Skip to main content
. Author manuscript; available in PMC: 2024 Dec 3.
Published in final edited form as: Ann Intern Med. 2022 May 17;175(7):918–926. doi: 10.7326/M21-3798

Figure 3.

Figure 3.

Vaccine impact measures and vaccine effectiveness for 4vHPV-type prevalence among sexually experienced 14- to 24-year-old females, in 3 vaccine eras.

4vHPV-type indicates quadrivalent HPV vaccine types: HPV 6, 11, 16, and 18. All estimates are weighted using NHANES (National Health and Nutrition Examination Survey) examination weights.

* Impact = (1 — prevalence ratio) · 100. Bars represent 95% CIs. The following impact estimates were calculated using prevalence estimates with relative SE >30% and should be interpreted with caution: population impact 2015–2018; impact among vaccinated persons in 2007–2010, 2011–2014, and 2015–2018; impact among unvaccinated persons in 2015–2018; and vaccine effectiveness in 2007–2010, 2011–2014, and 2015–2018.

† Vaccinated indicates self-/parent-reported receipt of ≥1 dose. 4vHPV = quadrivalent HPV vaccine; HPV = human papillomavirus.